This Article Résumé de cet Article Full Text Full Text (PDF) Submit a scholarly reply Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Samer, C. F. Articles by Desmeules, J. A. Search for Related Content PubMed PubMed Citation Articles by Samer, C. F. Articles by Desmeules, J. A.

Polymorphisme génétique et interactions médicamenteuses : leur importance dans le traitement de la douleur

[Genetic polymorphism and drug interactions: their importance in the treatment of pain]

Du Service de pharmacologie et toxicologie cliniques et Centre multidisciplinaire d’étude et de traitement de la douleur; Département d’Anesthésiologie, Pharmacologie et Soins intensifs de chirurgie, Hôpitaux Universitaires de Genève, Genève, Suisse.

Adresser la correspondance à: Dr Caroline Flora Samer, Service de pharmacologie et toxicologie cliniques, Hôpitaux Universitaires de Genève, 1211 Genève 14, Suisse. Téléphone : +41.22/382.99.34 ; Télécopieur : +41.22/382.99.45 ; Courriel : Caroline.Samer{at}hcuge.ch

Objectives: To evaluate the impact of certain genetic polymorphisms on variable responses to analgesics

Sources: Systematic review, by means of a structured computerized search in the Medline database (1966–2004). Key words: pharmacogenetics, polymorphism, cytochrome P450 (CYP), glycoprotein P (P-gp), pain, antalgics, opiates, morphine, codeine, tramadol, non-steroidal anti-inflammatory drugs (NSAID). Articles in English and French were selected. References in relevant articles were also retrieved.

Main findings: Most analgesics are metabolized by CYP isoenzymes subject to genetic polymorphism. NSAIDs are metabolized by CYP2C9; opioids described as "weak" (codeine, tramadol), anti-depressants and dextromethorphan are metabolized by CYP2D6 and some "potent" opioids (buprenorphine, methadone or fentanyl) by CYP3A4/5. After the usual doses have been administered, drug toxicity or, on the contrary, therapeutic ineffectiveness may occur, depending on polymorphism and the substance. Drug interactions mimicking genetic defects because of the existence of CYP inhibitors and inducers, also contribute to the variable response to analgesics.

Some opioids are substrates of P-gp, a transmembrane transporter also subject to genetic polymorphism. However, P-gp could only play a minor modulating role in man on the central effects of morphine, methadone and fentanyl.

Conclusion: In the near future, pharmacogenetics should enable us to optimize therapeutics by individualizing our approach to analgesic drugs and making numerous analgesics safer and more effective. The clinical usefulness of these individualized approaches will have to be demonstrated by appropriate pharmacoeconomic studies and analyses.